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The American Heart Association (AHA) and the 
American College of Cardiology (ACC) have just issued 
(September 23, 2014) new guidelines for the management 
of patients with non-ST elevation (NSTE) acute coronary 
syndromes (ACS).1 They start with definitions. Absence of 
persistent ST elevation defines NSTE-ACS (except in 
patients with true posterior myocardial infarction –MI). 
Further classification of NSTE-ACS is based on whether 
cardiac troponin is elevated (NSTEMI) or not (unstable 
angina - UA). ST depression, transient ST elevation, 
and/or T-wave inversion may be present but are not 
required for a diagnosis of NSTEMI. Abnormalities on the 
electrocardiogram (ECG) and elevated cardiac troponins in 
isolation are insufficient to make the diagnosis of ACS but 
must be interpreted in the appropriate clinical context.1,2 
Thus, UA and NSTEMI differ primarily by whether 
ischemia causes myocardial damage with a detectable 
cardiac biomarker. With the increasing sensitivity of 
cardiac troponin assays, biomarker-negative ACS (UA) is 
becoming rarer.  
The recommendation for clinical assessment and initial 
evaluation is as follows: “Patients with suspected ACS 
should be risk stratified based on the likelihood of ACS 
and adverse outcome(s) to decide on the need for 
hospitalization and assist in the selection of treatment 
options” (Class I / Level of Evidence-LOE: B).  
For risk stratification, guidelines advocate the use of 
tools such as the TIMI risk score and the Global Registry 
of Acute Coronary Events (GRACE) risk score. An 
attempt should be made to identify low-risk patients with 
chest pain who are not having an ACS and who may safely 
be discharged home early. With regards to discharging or 
triaging patients from the emergency room (ER), the 
guidelines recommend to observe patients with symptoms 
consistent with ACS but without evidence of myocardial 
ischemia on ECG and with normal cardiac troponin, in a 
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chest or telemetry unit with serial ECGs and cardiac 
troponin at 3- to 6-hour intervals (Class IIa / LOE: B). For 
patients with possible ACS who have normal serial ECGs 
and cardiac troponins, it is recommended to have a 
treadmill ECG (LOE: A), or stress myocardial perfusion 
imaging, or stress echocardiography before discharge or 
within 72 hours after discharge (LOE: B). Indeed, low-risk 
patients can be discharged home and may be referred for 
outpatient testing.  
Differential diagnosis of the causes of chest pain is 
provided and emphasis is placed on history and physical 
examination to aid in diagnosis of ACS. In patients with 
symptoms suggestive of ACS, a 12-lead ECG should be 
performed and evaluated for ischemic changes within 10 
minutes of the patient’s arrival in the ER. If the initial ECG 
is normal (1-6%), it should be repeated, e.g., at 15- to 30- 
minute intervals during the first hour, especially if 
symptoms recur. Indeed, when the ischemia is due to left 
circumflex or right coronary artery occlusions, the 12-lead 
ECG may be normal, in which case a 15-lead ECG by 
obtaining additional posterior ECG leads (V7 - V9) may be 
helpful.1,3 Right-sided leads (V3R - V4R) are helpful in the 
case of inferior ST-elevation MI (STEMI) to detect right 
ventricular infarction. Left ventricular (LV) hypertrophy, 
bundle-branch blocks with repolarization abnormalities, 
and ventricular pacing may mask signs of ischemia.  
Emphasis is placed on the use of troponin improving 
the diagnostic accuracy. A rising and/or falling pattern in 
cardiac-specific troponin (troponin I or T) levels should be 
sought by obtaining measurements on arrival in the ER and 
3-6 hours after symptom onset in all patients who present 
with symptoms consistent with ACS. A negative cardiac 
troponin obtained with high-sensitivity assays confers a 
negative predictive value ≥99%.1,4 In patients with normal 
troponin, additional troponin levels should be obtained 
beyond 6 hours after symptom onset when there is a high 
index of suspicion for ACS based on ECG changes and/or 
clinical symptoms. The following is an important 
statement of the new guidelines: “With contemporary 
troponin assays, creatine kinase myocardial isoenzyme 
(CK-MB) and myoglobin are not useful for diagnosis of 
ACS”. With regards to estimating infarct size without 
measuring CK, the guidelines point to remeasuring 
troponin once on day 3 - 4 in patients with MI as an index 
of infarct size.  
Among the imaging studies that are recommended to 
guide differential diagnosis, emphasis is placed on chest 
X-ray (for pulmonary causes of chest pain and aortic 
dissection), chest computed tomography (CT) (for 
pulmonary embolism and aortic dissection), transthoracic 
echocardiography (for pericardial effusion and also for 
regional wall motion abnormalities), and transesophageal 
echocardiography (for aortic dissection). Importantly, 
these guidelines indicate that in low-risk patients with 
chest pain, coronary CT angiography can result in a more 
expedient and cost-effective diagnosis than stress 
myocardial scintigraphy.  
Admission for inpatient management is the standard of 
care for patients who present with NSTE-ACS. The goals 
of treatment are the immediate relief of ischemia and the 
prevention of MI and death. Medical treatment includes 
antianginal, antiplatelet, and anticoagulant agents.  
An early invasive or ischemia-guided approach (instead 
of an “initial conservative management”) is recommended 
for management of patients NSTE-ACS. Patients with 
continuing angina, hemodynamic instability, uncontrolled 
arrhythmias, or a large MI should be admitted to a 
coronary care unit (CCU). An assessment of LV function 
is recommended because depressed LV function will likely 
influence pharmacological therapies or choice of 
revascularization.  
An urgent/immediate invasive strategy, starting with 
diagnostic angiography and intending to proceed with 
percutaneous coronary intervention (PCI), if appropriate, 
is indicated in patients with NSTE-ACS who have 
refractory angina or hemodynamic or electrical instability 
and absent serious comorbidities or contraindications to 
these procedures. An early invasive strategy is also 
indicated in initially stabilized patients with NSTE-ACS 
who have an increased risk for clinical adverse events. An 
early invasive strategy is not recommended in patients with 
extensive comorbidities (e.g., hepatic, renal, pulmonary 
failure, cancer), in whom the risks of revascularization and 
comorbid conditions are likely to outweigh the benefits of 
revascularization. Also, an invasive strategy is not 
recommended in those with acute chest pain and a low 
likelihood of ACS who are troponin-negative, particularly 
women. In both strategies, patients should receive optimal 
anti-ischemic and antithrombotic medical therapy. In the 
invasive strategy, the optimal timing of coronary 
angiography has not been clearly defined. In general, there 
are 2 options: early invasive (i.e., within 24 hours) or 
delayed invasive (i.e., within 24 to 72 hours). The 
ischemia-guided strategy seeks to avoid the routine early 
use of invasive procedures unless patients experience 
refractory or recurrent ischemic symptoms or develop 
hemodynamic instability. When the ischemia-guided 
strategy is followed, noninvasive evaluation is performed 
and if severe ischemia occurs at a low threshold of stress, 
the patient is promptly referred for coronary angiography 
and revascularization. By following the ischemia-guided 
strategy, some patients get stabilized and will not require 
an invasive procedure and thus avoid its attendant cost and 
risk. However, several studies and meta-analyses have 
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indicated that a strategy of routine invasive therapy is 
generally superior to an ischemia-guided strategy or 
selectively invasive approach. The invasive strategy 
demonstrated its greatest advantage in the highest-risk 
stratum of patients, with no significant benefit on mortality 
over the noninvasive approach in moderate- and low-risk 
patients. An ischemia-guided strategy has been used with 
favorable results in initially stabilized patients with NSTE-
ACS at high risk for clinical events, including those with 
positive troponin levels. 
Oral beta-blocker therapy should be started within the 
first 24 hours in patients with no contraindications, such as 
signs of heart failure, evidence of low-output state, 
increased risk for cardiogenic shock, or other 
contraindications to beta blockade, e.g., first degree (PR 
interval >0.24 s), second- or third-degree AV block, active 
asthma, or reactive airway disease. In patients with a 
contraindication to beta blockers or those who have 
recurrent ischemia despite use of beta-blockers and 
nitrates, a non-dihydropyridine calcium channel blocker 
(e.g., verapamil or diltiazem) should be given as initial 
therapy in the absence of clinically significant LV 
dysfunction, increased risk for cardiogenic shock, PR 
interval >0.24 s, or second- or third degree AV block. 
(Class I / LOE: B). Angiotensin converting enzyme (ACE) 
inhibitors or angiotensin receptor blockers (ARBs) for 
those who are ACE inhibitor intolerant, should be started 
and continued indefinitely in all patients with LV ejection 
fraction <40% and in those with hypertension, diabetes 
mellitus, or stable chronic kidney disease (CKD) (Class I / 
LOE: A). In these latter patients, additional therapy with 
aldosterone blockade is recommended when post–MI and 
without significant renal dysfunction (creatinine >2.5 
mg/dL in men or >2.0 mg/dL in women) or hyperkalemia 
(K >5.0 mEq/L) (Class I / LOE: A). High-intensity statin 
therapy should be initiated or continued in all patients with 
NSTE-ACS and no contraindications to its use. 
In patients with NSTE-ACS, anticoagulation, in 
addition to antiplatelet therapy, is recommended for all 
patients (Class I) in the form of·either subcutaneous (sc) 
enoxaparin (LOE: A), or intravenous (IV) bivalirudin 
(LOE: B), or fondaparinux (LOE: B) (if PCI is performed 
additional unfractionated heparin-UFH or bivalirudin is 
needed) (LOE: B), or UFH (LOE: B). An anticoagulant 
should be administered to patients with NSTE-ACS 
undergoing PCI to reduce the risk of intracoronary and 
catheter thrombus formation (Class I / Level of Evidence: 
C).  
The guidelines also discuss the newer more potent 
antithrombotics and anticoagulants that reduce the risk of 
major adverse cardiac outcomes vs the increased risk of 
bleeding. Dual antiplatelet therapy with a P2Y12 inhibitor, 
either clopidogrel or one of the newer agents, ticagrelor or 
prasugrel, in addition to aspirin should be administered for 
up to 1 year to all patients with NSTE-ACS without 
contraindications who are treated with either an early 
invasive or ischemia-guided strategy. P2Y12 inhibitor 
therapy (clopidogrel, prasugrel, or ticagrelor) should be 
continued for at least 1 year in post–PCI patients treated 
with coronary stents. It is reasonable to use ticagrelor in 
preference to clopidogrel for P2Y12 treatment in patients 
with NSTE-ACS who undergo an early invasive or 
ischemia-guided strategy. It is also reasonable to choose 
prasugrel (initiated during PCI) over clopidogrel for P2Y12 
treatment in patients with NSTE-ACS who undergo PCI 
who are not at high risk of bleeding complications.  
 In patients with NSTE-ACS, anticoagulation, in 
addition to antiplatelet therapy, is recommended for all 
patients irrespective of initial treatment strategy. In 
patients with NSTE-ACS, anticoagulant therapy should be 
discontinued after PCI unless there is other reason to 
continue such therapy. With regards to use of glycoprotein 
(GP) IIb/IIIa inhibitors (abciximab, eptifibatide, or 
tirofiban), the guidelines recommend their use in patients 
with NSTE-ACS and high-risk features (e.g., elevated 
troponin) and not adequately pretreated with clopidogrel 
or ticagrelor (Class I / LOE: A).  
Patients with atrial fibrillation who develop NSTE ACS 
and receive a coronary stent are a special and important 
group at increased risk of bleeding as they are in need of 
triple antithrombotic (anticoagulant/antiplatelet) therapy. 
Withdrawing aspirin from triple therapy may decrease the 
risk,5 but confirmation studies are lacking. Also the issue 
of using the new oral anticoagulants in these patients 
remains moot.6  
The guidelines also refer to specific groups of patients, 
including women, older patients (>75 years), heart failure 
patients, patients with arrhythmias, patients in cardiogenic 
shock, diabetics and their adjunctive therapies, post-
CABG patients, patients with perioperative NSTE-ACS 
related to noncardiac surgery, patients with CKD and 
issues with antiplatelet therapy in this group, patients with 
anemia/bleeding/transfusion or thrombocytopenia, 
cocaine and methamphetamine users, and patients with 
vasospastic (Prinzmetal) angina. A specific group are 
patients with NSTE-ACS who have angiographically 
normal or nonobstructive CAD, a group in which women 
predominate. Also patients with stress (Takotsubo) 
cardiomyopathy, obese patients and patients taking 
antineoplastic/immunosuppressive therapy are discussed 
separately. Instructions are also given for the 
pneumococcal vaccine recommended for patients >65 
years of age and in high-risk patients with cardiovascular 
disease, for use of non-steroidal anti-inflammatory agents 
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(NSAIDs), use of hormone therapy, use of vitamins, and 
influenza vaccination.  
Post-hospital discharge advice and instructions should 
be provided to all patients with ACS, including advice for 
medication adherence, aggressive risk factor modification, 
proper follow-up with the healthcare team, appropriate 
dietary and physical activities, compliance with 
interventions for secondary prevention, and plan for a 
rehabilitation program. In addition to detailed instructions 
for daily exercise, patients should be given specific 
instruction on activities (e.g., lifting, climbing stairs, yard 
work, and household activities) that are permissible and 
those to avoid. Specific mention should be made of 
resumption of driving, return to work, and sexual activity 
(http://www.cardiosource.org/en/Science-And-Quality/Journal-
Scan/2014/09/2014-AHA-ACC-Guideline-for-the-
Management-of-NSTE-ACS.aspx).  
 The guidelines provide summary tables with up-to-date 
and easily accessible information. They include tables with 
risk scores (TIMI, GRACE), early risk stratification, 
cardiac biomarkers, recommendations for early hospital 
care, recommendations for initial antiplatelet/ 
anticoagulant therapy, factors associated with appropriate 
selection of early invasive strategy or ischemia-guided 
strategy, dosing of parenteral anticoagulants during PCI, 
plan of care for patients with NSTE-ACS, and a summary 
of recommendations for special patient groups. A pedantic 
management algorithm and an algorithm with a stepped-
care approach to pharmacological therapy for 
musculoskeletal symptoms in patients with known 
cardiovascular disease or risk factors for ischemic heart 
disease are also provided. In the appendix we find 
additional tables on universal classification of MI, 
pharmacological therapy in older patients with NSTE-
ACS, age-related physiological changes and their clinical 
impact in older patients with NSTE-ACS, and the key 
outcomes at 2 and 5 years after randomization of the 
FREEDOM Trial.  
Finally, the guidelines discuss quality of care and 
outcomes for ACS—use of performance measures and 
registries, and acknowledge the need for an individualized 
patient care.  
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